RnRMarketResearch.com adds "Hepatitis C - Pipeline Review, H1 2015" therapeutic market research report of 639 pages with latest updates, data and information to its online business intelligence library.
The report "Hepatitis C - Pipeline Review, H1 2015" provides an overview of the Hepatitis C's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
Hepatitis C is a liver disease caused by the hepatitis C virus. The virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. There are many types of hepatitis C virus. The most common in the U.S. is type 1. No type is more serious than any other, but they respond differently to treatment. Hepatitis C is an increasing public health concern in the United States and throughout the world. Symptoms of Hepatitis C include jaundice, stomach pain, loss of appetite, nausea and fatigue. 3, 50,000 to 5, 00,000 people die each year from hepatitis C-related liver diseases.
Labels: acute infection, chronic, hepatitis C, liver disease